
InnoScot Health has highlighted the contribution of NHS Scotland’s sustainability programme to the country’s wider transition towards a net zero …

NHS England has approved the routine commissioning of delayed-release mercaptamine bitartrate for eligible patients with nephropathic cystinosis, providing an additional …

The Medicines and Healthcare products Regulatory Agency (MHRA) has announced that two investigational medicines targeting liver cancer and dementia with …

NHS Golden Jubilee has become the first hospital in Scotland to introduce a light-activated nasal therapy designed to reduce the …

Manchester University NHS Foundation Trust has launched a specialist nurse-led clinic designed to provide more personalised follow-up care for kidney …

Androlabs has partnered with French men’s health specialist Majorelle to commercialise Testavan, a testosterone replacement therapy for adult men with …

Promatix Biosciences has secured funding through Innovate UK’s Biomedical Catalyst programme to support preclinical development of its lead bispecific antibody-drug …

NanoSomiX and Beckman Coulter Diagnostics have announced plans to collaborate on the development of next-generation immunoassays for neurodegenerative diseases using …

TrialAssure has announced that its ANONYMIZE platform has been selected by the European Medicines Agency (EMA) for use as an …

Researchers at Imperial College London and The University of Manchester have developed a new family of antifungal compounds that demonstrated …

Lonza and Engitix have entered into a licensing agreement to support the development of antibody-drug conjugates (ADCs), combining Engitix’s extracellular …

Cizzle Biotechnology has launched the commercial rollout of its CIZ1B Biomarker Blood Test for lung cancer in Texas in the …

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved the world’s first pressurised metered dose inhalers (pMDIs) to use …

Samsung Biologics has launched an all-cash public tender offer to acquire PolyPeptide Group in a deal valued at approximately CHF1.46bn, …

Novogenia AG has broken ground on a new headquarters and laboratory campus in Hallwang, Austria, designed to expand its capabilities …